180 Life Sciences Corporate Media Kit

12 TNFR2 cell membrane extracellular intracellular Anti-TNF *Use-of patent issued for DD, patent pending for unique delivery system, current program TNF Anti-TNFR2 mab * patent pending, future program TNF Wnt activation leading to FIBROSIS (↑ expression of a-SMA, Col1A1 genes etc) UNEXPECTED DISCOVERY – TNF/TNFR2 signaling activates Wnt pathway and transcription of fibrosis genes. Verjee…Nanchahal (2013) 180 LS drugs block TNF induced activation of pro- fibrotic pathways to reduce fibrosis Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target Liaquat S. Verjee a , Jennifer S.N. Verhoekx a,b , James K. K. Chan a , Thomas Krausgruber a , Vicky Nicolaidou a , David Izadi a , Dominique Davidson c , Marc Feldmann a, 1 , Kim S. Midwood a , and Jagdeep Nanchahal a, 1 a Kennedy Institute of Rheumatology, University of Oxford, London W6 8LH, United Kingdom b Department of Plastic and Rescontructive Surgery, Erasmus Medical Centre, 3015, Rotterdam, The Netherlands c Department of Plastic Surgery, St John’s Hospital, Livingston EH54 6PP, United Kingdom Rationale for TNF Blockade in Fibrosis 180 Life Sciences Corp. www.180lifesciences.com Q4 2020